Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
North America Scar Treatment Market – Insights
Healing of damaged tissues or wounds may create marks on the skin. These marks are referred as scars. Burn injury or other trauma condition, including surgery can also lead to a scar. Scars may be raised or recessed, different in color or texture from the surrounding healthy tissue, or particularly noticeable due to their size, shape, or location.
North America scar treatment market is estimated to account for US$ 3,731.9 Mn in terms of value in 2019 and is expected to reach US$ 5,043.8 Mn by the end of 2027.
North America Scar Treatment Market: Drivers
Increasing incidents of burns is expected to boost growth of North America scar treatment market over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC), 1.1 million burn injuries require medical attention in the U.S. annually and around 10,000 people in the U.S. die annually of burn-related infections.
Increasing number of accidents and surgeries is also expected to boost growth of the market. For instance, according to 2018 Fatal Motor Vehicle Crashes: Overview by National Highway Traffic Safety Administration, a U.S. federal agency, 10,511 deaths were registered in the U.S. in 2018.
U.S. held dominant position in North America scar treatment market in 2018, accounting for 87.9% share in terms of value, followed by Canada.
North America Scar Treatment Market: Restraints
High cost of laser treatment is expected to hamper growth of North America scar treatment market over the forecast period. For instance, according to the American Society of Plastic Surgeons, the average cost for laser skin resurfacing, which includes scar treatment, is US$ 2,071 for an ablative laser, whereas the average price for non-ablative laser treatment is US$ 1,144.
Moreover, scar treatment can lead to several side effects, which are also expected hinder growth of the market. Side effects of ablative laser resurfacing include temporary burning discomfort, oozing, crusting, ulceration, erythema, edema, acneiform eruptions, eczematous dermatitis, and infections. Side effects of non-ablative laser include transient erythema, blistering, crusting, scarring, post-inflammatory hyperpigmentation, and post-treatment purpura lasting for up to one week.
North America Scar Treatment Market: Opportunities
Increasing demand for prescription products for scar treatment is expected to offer lucrative growth opportunities for players in North America scar treatment market. Majority of the populace in North America prefer to consult qualified dermatologists and opt for prescribed products rather than using over-the-counter cosmetic products for the treatment of scars.
Moreover, technological advancements in the treatment of organ scarring is also expected to boost growth of the market. For instance, in December 2019, in the journal Cell Reports, researchers from the University of California Los Angeles reported development of accurate model of organ scarring using stem cells in a lab.
Topical sub segment in product type segment in North America scar treatment market was valued at US$ 2,222.8 Mn in 2018 and is expected to reach US$ 3,061.4 Mn by 2027 at a CAGR of 3.6% during the forecast period.
Market Trends/Key Takeaways
The demand for silicon-based products is increasing in the market for scar treatment. This is owing to the ability of these products to reduce the size and darkness of scars and protect the wound from moisture and further infection. Moreover, silicone gel sheets are biocompatible (with extended wear time), repositionable, resistant to microbial growth and hydrophobicity, and are effective in treatment of burn scars, post-surgical scars, and wound scars.
The market is also witnessing increasing adoption of ablative laser resurfacing (ALR) and non-ablative fractional lasers (NAFL) as the approach can offer improvement in the pigmentation and thickness of surgical scars, atrophic scars, hypertrophic scars, and hypopigmented scars. Moreover, use of ALR is effective for the treatment of traumatic and surgical scars.
- As stated by FDA, silicon sheeting for scar management is classified as class 1 device, which is considered the safest classification and does not require prescription and certification outside the U.S.
- The device is exempt from the premarket notification procedures
- Scar sheets are subject to general controls such as good manufacturing techniques, manufacturer’s registration with the FDA, proper branding and labelling, and general reporting procedures
- According to FDA, in case of lasers, the manufacturers of electronic radiation emitting products that are sold in the U.S. are expected to comply to the Federal Food, Drug and Cosmetic Act (FFDCA), Chapter V, Subchapter C - Electronic Product Radiation Control guidelines
North America Scar Treatment Market: Competitive Landscape
Major players operating in North America scar treatment market include, Smith & Nephew Inc., Merz Inc., Enaltus LLC, Oculus Innovative Sciences, Inc., CCA Industries, Cynosure, Inc., Avita Medical, Lutronics, Janssen Biotech, Inc., Luminus Inc., Syneron Medical Ltd., and NutraMarks, Inc.
North America Scar Treatment Market: Key Developments
Key players in the market are focused on product launch and assessment to expand their product portfolio. For instance, in June 2019, AVITA Medical, a regenerative medicine company, announced new preliminary RECELL Autologous Cell Harvesting Device (RECELL System) data at the 24th annual World Congress of Dermatology Meeting. The RECELL system is used in the treatment of vitiligo and facial acne scars.
Key players in the market are focused on adopting inorganic growth strategies to expand their product portfolio. For instance, in December 2019, Janssen Biotech, Inc. entered a definitive agreement to acquire all rights to the investigational compound bermekimab – an anti-IL-1alpha monoclonal antibody for the treatment of atopic dermatitis and hidradenitis suppurativa— from XBiotech Inc.